Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced fusion-positive non-small-cell lung cancer and thyroid cancer, and -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced fusion-positive non-small-cell lung cancer and thyroid cancer, and -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Background: Patient-reported outcomes (PROs) are increasingly becoming an important part of clinical trials as they are helpful in analyzing the safety and efficacy of treatment in chronic diseases like cancer. Objectives: We report PROs and health-related quality of life (HRQoL) with selpercatinib...

Full description

Bibliographic Details
Main Authors: Shun Lu, Xiangqian Zheng, Yuping Sun, Dingzhi Huang, Lin Wu, Qinghai Ji, Chengzhi Zhou, Jianying Zhou, Ye Guo, Minghua Ge, Ding Ding, Jingxin Shao, Wanli Zhang, Ming Gao, Ying Cheng
Format: Article
Language:English
Published: SAGE Publishing 2023-08-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359231189429

Internet

https://doi.org/10.1177/17588359231189429

Similar Items